SWOG clinical trial number
C9741

A Randomized Phase III Trial of Sequential Chemotherapy Using Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or 21 Day Intervals in Women with Node Positive Stage II/IIIA Breast Cancer

Closed
Phase
Published
Abbreviated Title
Sequential vs. concurrent Tx in Stage II/IIA Breast
Activated
07/01/1998
Closed
03/31/1999
Participants
NCORP, Members, Medical Oncologists, Pathologists, Affiliates

Research committees

Breast Cancer

Treatment

Cyclophosphamide Allopurinol Fludarabine Phosphate Rituximab CC-5013 (Lenalidomide)

Publication Information Expand/Collapse

2016

PAM50 gene signatures are prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy in C9741 (Alliance)

MC Liu;BN Pitcher;ER Mardis;SR Davies;JE Snider;TL Vickery;JP Reed;K DeSchryver;B Singh;PN Friedman;WJ Gradishar;EA Perez;S Martino;M Citron;L Norton;EP Winer;CA Hudis;LA Carey;TO Nielsen;CM Perou;MJ Ellis;WT Barry NPJ Breast Cancer 2016;2. pii: 15023. doi: 10.1038/npjbcancer.2015.23.

PMid: PMID28691057 | PMC number: PMC5501351

2015

Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer Patients Receiving Chemotherapy: Results from CALGB 9741 (ALLIANCE)

JA Ligibel;CT Cirrincione;M Liu;ML Citron;JN Ingle;W Gradishar;S Martino;W Sikov;R Michaelson;E Winer;C Hudis;D Berry;WT Berry Journal of the National Cancer Institute Jun 25;107(9) pii: djv179. doi: 10.1093/jnci/djv179

PMid: PMID26113580 | PMC number: PMC4651106

2011

Cancer and Leukemia Group B pathology committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues [PMID21519016; PMC3107745]

D Rimm;T Nielsen;S Jewel;D Rohrer;G Broadwater;F Waldman;K Mitchell;B Singh;G Tsongalis;W Frankel;W Magliocco;J Lara;E Hsi;I Bleiweiss;S Badve;B Chen;P Ravdin;R Schilsky;A Thor;D Berry Journal of Clinical Oncology 29(16):2282-2290

2005

Dose-dense (DD)AC followed by paclitaxel is associated with moderate frequent anemia compared to sequential (S) and/or less DD Treatment: update by CALGB on breast cancer intergroup trial C9741 with ECOG, SWOG, & NCCTG

ML Citron;DA Berry;C Cirrincione;RB Livingston;W Gradishar;E Perez;H Muss;L Norton;E Winer;C Hudis Proc of the ASCO, JCO 23(16S):33s (#620)

Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective.

C Hudis;M Citron;D Berry;C Cirrincione;W Gradishar;N Davidson;S Martino;R Livingston;J Ingle;E Perez;J Abrams;R Schilsky;M Ellis;H Muss;L Norton;E Winer Breast Cancer Research and Treatment 94(Suppl 1):S20-S21(#41)

2003

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/ Cancer and Leukemia Group B Trial 9741

ML Citron;DA Berry;C Cirrincione;C Hudis;EP Winer;WJ Gradishar;NE Davidson;S Martino;R Livingston;JN Ingle;EA Perez;J Carpenter;D Hurd;JF Holland;BL Smith;CI Sartor;EH Leung;J Abrams;RL Schilsky;HB Muss;L Norton Journal of Clinical Oncology 21(8):1431-1439